Concurrent celecoxib versus placebo in patients with stage II-III non-small cell lung cancer: a randomised phase II trial.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 17532073.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In several pre-clinical models, cyclooxygenase (COX) inhibitors increase radio-sensitivity of tumours, whilst not affecting normal tissues. A randomised phase II trial comparing concurrent radiotherapy with either celecoxib or placebo in patients with stage II-III non-small cell lung cancer was therefore initiated. Because of poor recruitment, the study was stopped after the enrollment of 41 patients, instead of the foreseen 102. None of the endpoints differed significantly between both groups. However, due to the limited number of patients, no definitive conclusions can be drawn.
Medical subject headings
- Carcinoma, Non-Small-Cell Lung
- Cyclooxygenase Inhibitors
- Lung Neoplasms
- Pyrazoles
- Radiation-Sensitizing Agents
- Sulfonamides